ScreenerHero

MDNA Medicenna Therapeutics Corp.

TSX · CA · Healthcare · Biotechnology · medicenna.com
0.4350CAD+6.10%Mkt Cap: 29.24M $P/E: —

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap29.24M USD
Enterprise Value21.81M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.41M USD
Revenue/Share—
Last Price0.4350 CAD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees15
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.67
PEG—
EV/EBITDA-1.34
EV/Revenue—
P/S—
P/B21.39
EPS (TTM)-0.22
EPS (Forward)-0.23
52W Range
0.33506% of range1.970
52W High1.970 CAD
52W Low0.3350 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-741.70%
ROA-217.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.05M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-26.88%
Net Debt-4.07M USD
Net Debt/EBITDA0.25
Balance Sheet
Debt/Equity0.05
Current Ratio1.25
Quick Ratio1.11
Book Value/Sh0.02 CAD
Cash/Share0.06 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 3, 2017
Analyst Consensus
Rating—
Target (Mean)3.200 CAD
Upside (mean)+635.6%
Target Range1.600 CAD – 4.000 CAD
1.600+635.6% to mean4.000
# Analysts3
Ownership
Shares Out.92.30M
Float74.34M
Insiders18.82%
Institutions0.00%
Short Interest
Short Ratio3.1d
Short % Float0.38%
Short % Out.0.16%
Shares Short145.37K
Short (prev mo.)295.76K
Technical
SMA 500.4112 (+5.8%)
SMA 2000.6060 (-28.2%)
Beta1.96
S&P 52W Chg14.58%
Avg Vol (30d)45.86K
Avg Vol (10d)23.41K
Technical Indicators
RSI (14)57.6
MACD-0.0030
MACD Signal-0.0023
MACD Hist.-0.0006
BB Upper0.4688 CAD
BB Middle0.4170 CAD
BB Lower0.3651 CAD
BB Width24.87%
ATR (14)0.0240 CAD
Vol Ratio (20d)9.95x